Marshall Wace LLP Grows Stock Holdings in Agilent Technologies, Inc. $A

Marshall Wace LLP increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 2.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,511,123 shares of the medical research company’s stock after acquiring an additional 42,476 shares during the quarter. Marshall Wace LLP’s holdings in Agilent Technologies were worth $178,328,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Resona Asset Management Co. Ltd. lifted its position in Agilent Technologies by 6.2% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock worth $11,631,000 after acquiring an additional 5,767 shares during the period. TrueMark Investments LLC acquired a new stake in shares of Agilent Technologies in the second quarter worth $1,999,000. Nuance Investments LLC raised its holdings in shares of Agilent Technologies by 13.5% during the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock worth $9,523,000 after purchasing an additional 9,628 shares during the last quarter. Fenimore Asset Management Inc lifted its position in Agilent Technologies by 2.7% during the second quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after purchasing an additional 4,823 shares during the period. Finally, Godsey & Gibb Inc. boosted its holdings in Agilent Technologies by 19.8% in the second quarter. Godsey & Gibb Inc. now owns 166,664 shares of the medical research company’s stock valued at $19,668,000 after purchasing an additional 27,520 shares during the last quarter.

Agilent Technologies Stock Down 0.8%

A opened at $148.08 on Friday. The company has a market cap of $41.98 billion, a PE ratio of 32.40, a price-to-earnings-growth ratio of 4.33 and a beta of 1.27. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $160.27. The company has a 50-day moving average price of $144.40 and a 200 day moving average price of $127.69. The company has a quick ratio of 1.52, a current ratio of 1.96 and a debt-to-equity ratio of 0.45.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, topping the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion during the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.Agilent Technologies’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be issued a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, January 6th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. Agilent Technologies’s payout ratio is 21.66%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Robert W. Baird boosted their price objective on Agilent Technologies from $142.00 to $165.00 and gave the company an “outperform” rating in a report on Tuesday, November 25th. Weiss Ratings restated a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Barclays boosted their target price on shares of Agilent Technologies from $145.00 to $165.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 25th. Finally, UBS Group lifted their price target on Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $161.08.

Insider Buying and Selling at Agilent Technologies

In other news, VP Rodney Gonsalves sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total transaction of $464,970.00. Following the completion of the sale, the vice president owned 31,846 shares of the company’s stock, valued at $4,935,811.54. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Padraig Mcdonnell sold 911 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $143.24, for a total transaction of $130,491.64. Following the transaction, the chief executive officer owned 32,058 shares in the company, valued at $4,591,987.92. The trade was a 2.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 16,401 shares of company stock worth $2,468,962.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.